# GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

Study · id `cardio:ct-nct03821129` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03821129](<https://clinicaltrials.gov/study/NCT03821129>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03821129

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 636 participants.

## Technical summary

Registry record NCT03821129. Allocation not applicable; no masking; primary purpose prevention. Start 2019-07-25 (actual); primary completion 2028-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 636 participants (planned count; ClinicalTrials.gov record NCT03821129, source copy `cardio:ctgov-nct03821129-2026-07-30`, retrieved 2026-10-26)
- Started: 2019-07-25 (actual) (ClinicalTrials.gov record NCT03821129, source copy `cardio:ctgov-nct03821129-2026-07-30`, retrieved 2026-10-26)
- Primary completion: 2028-10 (anticipated) (ClinicalTrials.gov record NCT03821129, source copy `cardio:ctgov-nct03821129-2026-07-30`, retrieved 2026-10-26)
- Completion: 2031-10 (anticipated) (ClinicalTrials.gov record NCT03821129, source copy `cardio:ctgov-nct03821129-2026-07-30`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03821129, source copy `cardio:ctgov-nct03821129-2026-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03821129-2026-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
- Acronym: REDUCE PAS
- Condition: Stroke
- Condition: PFO - Patent Foramen Ovale
- Intervention (Device): PFO closure with GORE® CARDIOFORM Septal Occluder
- Lead sponsor: W.L.Gore & Associates
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: W.L.Gore & Associates (`cardio:org-w-l-gore-associates`)

## Provenance

Content hash: 4a00beb190375def5eeec9d8b41c60d46ebd8644cc197962574d7c8a93dd9851
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
